NewLink Genetics shares plummet 44% after Merck, Incyte trial failure
BPC Staff Apr 6, 2018 | 8:23 pm
<1 min read time
56 wordsAll Latest News, Health and Wellness, Insurance, Statewide NewsMarketWatch: Shares of Ames-based NewLink Genetics Corp. plummeted 44 percent by late morning today after Merck and Incyte Corp. said their trial testing a combination including a type of cancer drug called an IDO inhibitor had failed. The companies are stopping the trial. NewLink stock had dropped 39 percent in premarket trade immediately after the announcement.
Trending News
